These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7116849)

  • 21. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma high-density-lipoprotein cholesterol levels during long-term use of an oral contraceptive in Nigerian women.
    Taylor GO; Agbedana EO; Ojo OA
    Br J Obstet Gynaecol; 1982 Nov; 89(11):944-7. PubMed ID: 7171504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of oral contraceptive steroids on serum lipids.
    De Alvarez RR; Jahed FM; Spitalny KJ; Elkin H; Jaunakais I
    Am J Obstet Gynecol; 1973 Jul; 116(5):727-49. PubMed ID: 4351501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women.
    Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B
    Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-I and B and glycosylated proteins.
    Bergink EW; Kloosterboer HJ; Lund L; Nummi S
    Contraception; 1984 Jul; 30(1):61-72. PubMed ID: 6236951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial.
    Notelovitz M; Feldman EB; Gillespy M; Gudat J
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1269-80. PubMed ID: 2655452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.
    Norris LA; Devitt M; Bonnar J
    Thromb Res; 1996 Feb; 81(4):407-17. PubMed ID: 8907290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins.
    Patsch W; Brown SA; Gotto AM; Young RL
    Am J Obstet Gynecol; 1989 Nov; 161(5):1396-401. PubMed ID: 2686455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a controlled exercise program on serum lipoprotein levels in women on oral contraceptives.
    Wynne TP; Frey MA; Laubach LL; Glueck CJ
    Metabolism; 1980 Dec; 29(12):1267-71. PubMed ID: 7453571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
    Skouby SO; Wagner HH; Andersen O
    Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
    Porcile A; Gallardo E
    Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.
    Cullberg G; Samsioe G; Andersen RF; Bredesgaard P; Andersen NB; Ernerot H; Fanøe E; Fylling P; Haack-Sørensen PE; Klottrup P; Pedersen JH; Sandager T
    Contraception; 1982 Sep; 26(3):229-43. PubMed ID: 6217028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring. II. Serum lipoproteins and apolipoproteins.
    Ahrén T; Lithell H; Victor A; Vessby B; Johansson ED
    Contraception; 1981 Oct; 24(4):451-68. PubMed ID: 6797786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for coronary heart disease and platelet functions.
    Renaud S
    Adv Exp Med Biol; 1984; 164():129-44. PubMed ID: 6695570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.